OBJECTIVES: The objective of this study is to analyze the clinical outcomes of abnormal cervical cytology and newly diagnosed human papillomavirus (HPV)-related disease after organ transplantation. MATERIALS AND METHODS: Medical records from July 2004 to August 2015 were reviewed, and thirteen patients were identified who had been newly diagnosed with HPV-related disease (cervical intraepithelial neoplasia [CIN] and cervical cancer) after organ transplantation. The median transition time to the aggravation of cervical cytology and the spontaneous regression rate of CIN were evaluated. Clinical outcomes of CIN1 and CIN2 were compared between the general population and patients with organ transplantation. We also reviewed the current literature regarding the incidence of HPV infection, Pap smear abnormality and/or CIN after organ transplantation. RESULTS: The cervical cytology aggravated in nine of the 13 patients (69 %). In seven of the 13 cases (54 %), treatments such as cervical conization, laser vaporization, or radiation therapy, were conducted. HPV-related disease disappeared after treatment in only three of the seven actively treated cases (43 %). In contrast, the lesions persisted in three (43 %) cases after treatment. One patient died from cervical cancer. The spontaneous regression rate of the HPV-related diseases, if left untreated, was 0 %. There was a statistically significant difference in the clinical outcomes of CIN1 and CIN2 between the general population and patients with organ transplantation (p = 0.0026 and 0.0315, respectively; chi-squared test). CONCLUSIONS: HPV-related lesions that are newly diagnosed after organ transplantation do not seem to regress as spontaneously as in the general population. Physicians should recognize the importance of close monitoring and long-term follow-up.
OBJECTIVES: The objective of this study is to analyze the clinical outcomes of abnormal cervical cytology and newly diagnosed human papillomavirus (HPV)-related disease after organ transplantation. MATERIALS AND METHODS: Medical records from July 2004 to August 2015 were reviewed, and thirteen patients were identified who had been newly diagnosed with HPV-related disease (cervical intraepithelial neoplasia [CIN] and cervical cancer) after organ transplantation. The median transition time to the aggravation of cervical cytology and the spontaneous regression rate of CIN were evaluated. Clinical outcomes of CIN1 and CIN2 were compared between the general population and patients with organ transplantation. We also reviewed the current literature regarding the incidence of HPV infection, Pap smear abnormality and/or CIN after organ transplantation. RESULTS: The cervical cytology aggravated in nine of the 13 patients (69 %). In seven of the 13 cases (54 %), treatments such as cervical conization, laser vaporization, or radiation therapy, were conducted. HPV-related disease disappeared after treatment in only three of the seven actively treated cases (43 %). In contrast, the lesions persisted in three (43 %) cases after treatment. One patient died from cervical cancer. The spontaneous regression rate of the HPV-related diseases, if left untreated, was 0 %. There was a statistically significant difference in the clinical outcomes of CIN1 and CIN2 between the general population and patients with organ transplantation (p = 0.0026 and 0.0315, respectively; chi-squared test). CONCLUSIONS:HPV-related lesions that are newly diagnosed after organ transplantation do not seem to regress as spontaneously as in the general population. Physicians should recognize the importance of close monitoring and long-term follow-up.
Entities:
Keywords:
CIN; Cancer screening; Cervical cytology; HPV; Immunosuppression; Organ transplantation
Authors: Aisling E Courtney; Niall Leonard; Ciaran J O'Neill; Peter T McNamee; Alexander P Maxwell Journal: Nephrol Dial Transplant Date: 2008-10-23 Impact factor: 5.992
Authors: Bree McAllum; Peter H H Sykes; Lynn Sadler; Helene Macnab; Bryony J Simcock; Adel K Mekhail Journal: Am J Obstet Gynecol Date: 2011-06-25 Impact factor: 8.661
Authors: K A P Meeuwis; L B Hilbrands; J IntHout; B F M Slangen; I M P Hendriks; F Hinten; M H L Christiaans; W G V Quint; P C M van de Kerkhof; L F A G Massuger; A J Hoitsma; M M van Rossum; W J G Melchers; J A de Hullu Journal: Am J Transplant Date: 2015-02-12 Impact factor: 8.086
Authors: Howard D Strickler; Joel M Palefsky; Keerti V Shah; Kathryn Anastos; Robert S Klein; Howard Minkoff; Ann Duerr; L Stewart Massad; David D Celentano; Charles Hall; Melissa Fazzari; Susan Cu-Uvin; Melanie Bacon; Paula Schuman; Alexandra M Levine; Amanda J Durante; Stephen Gange; Sandra Melnick; Robert D Burk Journal: J Natl Cancer Inst Date: 2003-07-16 Impact factor: 13.506
Authors: M Veroux; D Corona; G Scalia; V Garozzo; M Gagliano; G Giuffrida; C M Costanzo; A Giaquinta; I Palermo; D Zappalà; T Tallarita; D Zerbo; R Russo; A Cappellani; C Franchina; V Scriffignano; P Veroux Journal: Transplant Proc Date: 2009-05 Impact factor: 1.066
Authors: Michael J Silverberg; Wendy A Leyden; Aileen Chi; Steven Gregorich; Megan J Huchko; Shalini Kulasingam; Miriam Kuppermann; Anna Seto; Karen K Smith-McCune; George F Sawaya Journal: Obstet Gynecol Date: 2018-01 Impact factor: 7.661
Authors: Aleksandra Wielgos; Bronisława Pietrzak; Barbara Suchonska; Mariusz Sikora; Lidia Rudnicka; Miroslaw Wielgos Journal: Int J Environ Res Public Health Date: 2022-03-16 Impact factor: 3.390